atazanavir sulfate has been researched along with Nephrolithiasis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gatanaga, H; Hamada, Y; Kikuchi, Y; Kinai, E; Komatsu, H; Nishijima, T; Oka, S; Teruya, K; Tsukada, K; Watanabe, K | 1 |
| David, SG; Osterberg, EC; Rosoff, JS; Wang, LC | 1 |
| Aoki, T; Gatanaga, H; Hamada, Y; Honda, H; Joya, A; Kikuchi, Y; Kinai, E; Mizushima, D; Nishijima, T; Oka, S; Tanaka, N; Tanuma, J; Teruya, K; Tsuchiya, K; Tsukada, K; Watanabe, K; Yazaki, H | 1 |
| Cattaneo, D; Charbe, N; Clementi, E; Cozzi, V; Ferraris, L; Galli, M; Gervasoni, C; Landonio, S; Meraviglia, P; Minisci, D; Molinari, L; Riva, A; Rizzardini, G | 1 |
| Moreno, V; Valencia, ME | 1 |
| Bower, M; Gazzard, B; Mandalia, S; Nelson, M; Rockwood, N | 1 |
| Birnkrant, DB; Chan-Tack, KM; Struble, KA; Truffa, MM | 1 |
7 other study(ies) available for atazanavir sulfate and Nephrolithiasis
| Article | Year |
|---|---|
Ritonavir-boosted darunavir is rarely associated with nephrolithiasis compared with ritonavir-boosted atazanavir in HIV-infected patients.
Topics: Adult; Anti-HIV Agents; Atazanavir Sulfate; Darunavir; Female; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Proportional Hazards Models; Pyridines; Retrospective Studies; Ritonavir; Sulfonamides | 2013 |
Recurrent nephrolithiasis associated with atazanavir use.
Topics: Anti-HIV Agents; Atazanavir Sulfate; Calcium Oxalate; HIV Infections; Humans; Lithotripsy, Laser; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Pyridines; Recurrence; Stents; Tomography, X-Ray Computed; Ureteral Calculi; Ureteroscopy | 2014 |
Single-nucleotide polymorphisms in the UDP-glucuronosyltransferase 1A-3' untranslated region are associated with atazanavir-induced nephrolithiasis in patients with HIV-1 infection: a pharmacogenetic study.
Topics: 3' Untranslated Regions; Adolescent; Adult; Aged; Atazanavir Sulfate; Case-Control Studies; Female; Genotype; Genotyping Techniques; Glucuronosyltransferase; HIV Infections; HIV-1; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Polymorphism, Single Nucleotide; Pyridines; Young Adult | 2014 |
Metabolic and kidney disorders correlate with high atazanavir concentrations in HIV-infected patients: is it time to revise atazanavir dosages?
Topics: Adult; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Drug Administration Schedule; Drug Dosage Calculations; Drug Monitoring; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Hyperbilirubinemia; Male; Middle Aged; Nephrolithiasis; Ritonavir; Viral Load | 2015 |
[Atazanavir-induced nephrolithiasis].
Topics: Adenine; Adult; Alkynes; Antiretroviral Therapy, Highly Active; Atazanavir Sulfate; Benzoxazines; Cyclopropanes; Dideoxynucleosides; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis D, Chronic; HIV Infections; HIV Protease Inhibitors; Humans; Indinavir; Lamivudine; Lopinavir; Male; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Pyrimidinones; Reverse Transcriptase Inhibitors; Ritonavir; Stavudine; Tenofovir | 2009 |
Ritonavir-boosted atazanavir exposure is associated with an increased rate of renal stones compared with efavirenz, ritonavir-boosted lopinavir and ritonavir-boosted darunavir.
Topics: Alkynes; Anti-HIV Agents; Atazanavir Sulfate; Benzoxazines; Bilirubin; Cohort Studies; Cyclopropanes; Darunavir; Drug Therapy, Combination; HIV Infections; HIV Protease Inhibitors; Humans; Lopinavir; Nephrolithiasis; Oligopeptides; Pyridines; Pyrimidinones; Retrospective Studies; Ritonavir; Sulfonamides | 2011 |
Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System.
Topics: Adenine; Adult; Adverse Drug Reaction Reporting Systems; Atazanavir Sulfate; Drug Therapy, Combination; Female; HIV Infections; HIV Protease Inhibitors; Hospitalization; Humans; Male; Middle Aged; Nephrolithiasis; Oligopeptides; Organophosphonates; Pyridines; Reverse Transcriptase Inhibitors; Ritonavir; Tenofovir; United States | 2007 |